Suven Life Sciences Ltd - ESG Rating & Company Profile powered by AI
Other corporations in the scoring industry group for Suven Life Sciences Ltd are shownin the table. Full ESG assessment of Suven Life Sciences Ltd are accessed by registering for free. This Disclosure rating includes 17 UN Sustainable Development Goals including: 'Gender Equality', 'Industry, Innovation & Infrastructure' and 'Life below Water'.
Suven Life Sciences Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.4; made up of an environmental score of 5.3, social score of 8.0 and governance score of 6.0.
6.4
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
389 | WuXi Biologics (Cayman) Inc | 6.6 | High |
401 | Oxford Cannabinoid Technologies Holdings PLC | 6.5 | High |
402 | Suven Life Sciences Ltd | 6.4 | High |
402 | Capricor Therapeutics Inc | 6.4 | High |
402 | Alembic Pharmaceuticals Ltd | 6.4 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Suven Life Sciences Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Suven Life Sciences Ltd disclose current and historical energy intensity?
Does Suven Life Sciences Ltd report the average age of the workforce?
Does Suven Life Sciences Ltd reference operational or capital allocation in relation to climate change?
Does Suven Life Sciences Ltd disclose its ethnicity pay gap?
Does Suven Life Sciences Ltd disclose cybersecurity risks?
Does Suven Life Sciences Ltd offer flexible work?
Does Suven Life Sciences Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Suven Life Sciences Ltd disclose the number of employees in R&D functions?
Does Suven Life Sciences Ltd conduct supply chain audits?
Does Suven Life Sciences Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Suven Life Sciences Ltd conduct 360 degree staff reviews?
Does Suven Life Sciences Ltd disclose the individual responsible for D&I?
Does Suven Life Sciences Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Suven Life Sciences Ltd disclose current and / or historical scope 2 emissions?
Does Suven Life Sciences Ltd disclose water use targets?
Does Suven Life Sciences Ltd have careers partnerships with academic institutions?
Did Suven Life Sciences Ltd have a product recall in the last two years?
Does Suven Life Sciences Ltd disclose incidents of discrimination?
Does Suven Life Sciences Ltd allow for Work Councils/Collective Agreements to be formed?
Has Suven Life Sciences Ltd issued a profit warning in the past 24 months?
Does Suven Life Sciences Ltd disclose parental leave metrics?
Does Suven Life Sciences Ltd disclose climate scenario or pathway analysis?
Does Suven Life Sciences Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Suven Life Sciences Ltd disclose the pay ratio of women to men?
Does Suven Life Sciences Ltd support suppliers with sustainability related research and development?
Does Suven Life Sciences Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Suven Life Sciences Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Suven Life Sciences Ltd involved in embryonic stem cell research?
Does Suven Life Sciences Ltd disclose GHG and Air Emissions intensity?
Does Suven Life Sciences Ltd disclose its waste policy?
Does Suven Life Sciences Ltd report according to TCFD requirements?
Does Suven Life Sciences Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Suven Life Sciences Ltd disclose energy use targets?
Does Suven Life Sciences Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Suven Life Sciences Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Suven Life Sciences Ltd
These potential risks are based on the size, segment and geographies of the company.
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. It engages in drug discovery and development of new chemical entities (NCE) in central nervous system therapies. The company's product candidates include SUVN-502, which is in Phase II clinical trials for the treatment of Alzheimer's disease; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist, which has completed Phase I trials for the treatment of sleep and cognitive disorders; SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist, which has completed Phase I trials for the treatment of major depressive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist, which has completed Phase I trials for the treatment of depressive disorders. It is also developing SUVN-I6107 for the treatment of cognitive disorders, SUVN-M8036 for the treatment of psychiatric disorders, SUVN-D1044 for the treatment of gastrointestinal disorders, P2X7 Antagonist for the treatment of pain and inflammation, M4 PAM for the treatment of Psychosis, and 5-HT1A Partial Agonist for the treatment of resistant depression. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was founded in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.